Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.

@article{Socinski2002PhaseIT,
  title={Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.},
  author={Mark A. Socinski and Alan B. Sandler and Valerie K. Israel and Heidi H. Gillenwater and Langdon L. Miller and Paula K Locker and Alessandro Antonellini and Gary L. Elfring and Ronald B. Natale},
  journal={Cancer},
  year={2002},
  volume={95 7},
  pages={1520-7}
}
BACKGROUND This Phase II multicenter, open-label, single-arm study evaluated the efficacy and safety of a three-drug combination of irinotecan (CPT-11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC). METHODS Patients received repeated 21-day cycles at starting doses of paclitaxel 175 mg/m(2) administered over 3 hours, followed by carboplatin AUC of 5 over 30 minutes and CPT-11 at a starting dose level of 100 mg/m(2) over 90 minutes, all given on the first day of… CONTINUE READING